Intravenous Infusions (XGHA:IIL) Stock Based Compensation: GHS0.00 Mil (TTM As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Intravenous Infusions Stock Based Compensation?

Intravenous Infusions XGHA:IIL +8.86% Stock Based Compensation is GHS0.00 Mil as of . 20.

Intravenous Infusions's Stock Based Compensation for the six months ended in . 20 was GHS0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in . 20 was GHS0.00 Mil.

Intravenous Infusions Stock Based Compensation Related Terms

Intravenous Infusions Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Intravenous Infusions's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intravenous Infusions Stock Based Compensation Chart

Intravenous Infusions Annual Data
Trend
Stock Based Compensation

Intravenous Infusions Semi-Annual Data
Stock Based Compensation

Intravenous Infusions Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Stock Based Compensation for the trailing twelve months (TTM) ended in . 20 was GHS0.00 Mil.

What does a Stock Based Compensation of GHS0.00 Mil mean?
Intravenous Infusions (XGHA:IIL) has a Stock Based Compensation of GHS0.00 Mil as of . 20. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Intravenous Infusions and its competitors.
Is Intravenous Infusions' Stock Based Compensation too high?
Intravenous Infusions' current Stock Based Compensation is GHS0.00 Mil.
How does Intravenous Infusions' Stock Based Compensation compare to PTLF and PCYN?
Intravenous Infusions' Stock Based Compensation of GHS0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Intravenous Infusions and its competitors. Intravenous Infusions's current Stock Based Compensation is GHS0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intravenous Infusions stock overvalued right now?
Intravenous Infusions (XGHA:IIL) has a current Stock Based Compensation of GHS0.00 Mil. The current Stock Based Compensation is GHS0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Intravenous Infusions (XGHA:IIL), the current Stock Based Compensation is GHS0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Intravenous Infusions Business Description

Address Plot 4/7 Blk L, P.O Box KF 63, Effiduase-Koforidua, GHA
Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.